Ye Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ye Xu has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Cong Li
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
24 shared publicationsYun Xu
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
19 shared publicationsFangqi Liu
Department of Oncology, Shanghai Medical College Fudan University Shanghai China
18 shared publicationsSanjun Cai
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
13 shared publicationsTianan Guo
13 shared publications- Fangqi Liu
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center
12 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Laparoscopic versus open surgery for sphincter preservation in mid- and low rectal cancer: a large propensity score-matched cohort study
- 12 August 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessLaparoscopic versus open surgery for sphincter preservation in mid- and low rectal cancer: a large propensity score-matched cohort study
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (1) , 11
Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients
Background: Accurate assessment of mesorectal fascia (MRF) involvement status after neoadjuvant therapy (NAT) is critical for guiding post-NAT treatment. However, the discordance between magnetic resonance imaging (MRI)-based evaluations and histopathological results may drive overtreatment and complicate organ-preservation strategies. This study aimed to evaluate the association between post-NAT MRF involvement and pathological circumferential resection margin (CRM) positivity. Methods: This retrospective cohort study included treatment-naïve rectal cancer patients with MRI-confirmed MRF involvement between January 2014 and January 2024. All patients underwent MRI restaging after the NAT. The diagnostic performance, including sensitivity and specificity, of MRI-assessed MRF status was assessed to determine its efficacy in predicting pathological CRM positivity. Logistic regression and mixed-effects models were used to quantify the association between MRF status and CRM positivity. Cox regression analysis was used to assess the effect of MRF positivity on survival outcomes. Results: Among 506 enrolled patients, restaging MRI showed persistent MRF involvement in 50.2% (254/506). The CRM-positive rate was 10.2% in the MRF-positive group, compared to 1.6% in the MRF-negative group. Concordance between MRI and pathological assessment was poor (sensitivity: 0.867, specificity: 0.521, Kappa: 0.086). Nevertheless, MRF positivity independently predicted CRM positivity [odds ratio (OR): 6.228, 95% confidence interval (CI): 2.349–21.507, Pvs. 0.59; 3-year: 0.66 vs. 0.58; 5-year: 0.75 vs. 0.63]. Conclusions: MRI assessment of MRF involvement showed limited concordance with pathological CRM status after NAT. Integration of MRF status and RAS status refines prognostic stratification in non-metastatic MRF-positive rectal cancer, guiding subsequent treatment decisions.
- 1 February 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (1) , 11
Open AccessOverstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients
Background: Accurate assessment of mesorectal fascia (MRF) involvement status after neoadjuvant therapy (NAT) is critical for guiding post-NAT treatment. However, the discordance between magnetic resonance imaging (MRI)-based evaluations and histopathological results may drive overtreatment and complicate organ-preservation strategies. This study aimed to evaluate the association between post-NAT MRF involvement and pathological circumferential resection margin (CRM) positivity. Methods: This retrospective cohort study included treatment-naïve rectal cancer patients with MRI-confirmed MRF involvement between January 2014 and January 2024. All patients underwent MRI restaging after the NAT. The diagnostic performance, including sensitivity and specificity, of MRI-assessed MRF status was assessed to determine its efficacy in predicting pathological CRM positivity. Logistic regression and mixed-effects models were used to quantify the association between MRF status and CRM positivity. Cox regression analysis was used to assess the effect of MRF positivity on survival outcomes. Results: Among 506 enrolled patients, restaging MRI showed persistent MRF involvement in 50.2% (254/506). The CRM-positive rate was 10.2% in the MRF-positive group, compared to 1.6% in the MRF-negative group. Concordance between MRI and pathological assessment was poor (sensitivity: 0.867, specificity: 0.521, Kappa: 0.086). Nevertheless, MRF positivity independently predicted CRM positivity [odds ratio (OR): 6.228, 95% confidence interval (CI): 2.349–21.507, Pvs. 0.59; 3-year: 0.66 vs. 0.58; 5-year: 0.75 vs. 0.63]. Conclusions: MRI assessment of MRF involvement showed limited concordance with pathological CRM status after NAT. Integration of MRF status and RAS status refines prognostic stratification in non-metastatic MRF-positive rectal cancer, guiding subsequent treatment decisions.
- Open Access
- 25 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71042
Long‐Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer
Purpose: To compare the long‐term survival of patients with locally advanced low rectal cancer (LALRC), receiving neoadjuvant chemoradiotherapy (NCRT) versus adjuvant chemoradiotherapy (ACRT). Methods and Materials: This retrospective observational study included 1169 patients with LALRC (Stage II/III disease located ≤ 5 cm from the anal verge) who underwent diagnosis and treatment at Fudan University Shanghai Cancer Center from February 2006 to March 2021. In Stage II/III low rectal cancer patients, one‐to‐one matched pairs were created from the ACRT and NCRT groups using propensity score matching (PSM) based on baseline characteristics. OS and DFS were evaluated using the Kaplan–Meier method alongside the univariate Cox regression model. Results: In Stage II patients, 65 received ACRT and 107 received NCRT. For Stage III, 282 received ACRT and 715 received NCRT. After PSM, 45 paired Stage II patients and 243 paired Stage III patients were selected. In Stage II patients, there was no significant difference in OS and DFS between the groups. For Stage III, the 5‐ and 10‐year OS rates were 79.61% and 77.67% in the NCRT group, compared to 61.08% and 44.57% in the ACRT group ( p < 0.001). The 5‐ and 10‐year DFS rates were 69.93% and 65.26% in the NCRT group, versus 48.07% and 40.77% in the ACRT group ( p < 0.001). Additionally, in Stage III patients, NCRT was associated with a significant reduction in the risk of death and recurrence compared to ACRT (OS: HR = 0.47, p = 0.0001; DFS: HR = 0.55, p = 0.0001). Conclusion: For patients with Stage III low rectal cancer, NCRT significantly improved the long‐term DFS rate and OS rate, in comparison to adjuvant chemoradiotherapy.
- 25 July 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (15) , e71042
Open AccessLong‐Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer
Purpose: To compare the long‐term survival of patients with locally advanced low rectal cancer (LALRC), receiving neoadjuvant chemoradiotherapy (NCRT) versus adjuvant chemoradiotherapy (ACRT). Methods and Materials: This retrospective observational study included 1169 patients with LALRC (Stage II/III disease located ≤ 5 cm from the anal verge) who underwent diagnosis and treatment at Fudan University Shanghai Cancer Center from February 2006 to March 2021. In Stage II/III low rectal cancer patients, one‐to‐one matched pairs were created from the ACRT and NCRT groups using propensity score matching (PSM) based on baseline characteristics. OS and DFS were evaluated using the Kaplan–Meier method alongside the univariate Cox regression model. Results: In Stage II patients, 65 received ACRT and 107 received NCRT. For Stage III, 282 received ACRT and 715 received NCRT. After PSM, 45 paired Stage II patients and 243 paired Stage III patients were selected. In Stage II patients, there was no significant difference in OS and DFS between the groups. For Stage III, the 5‐ and 10‐year OS rates were 79.61% and 77.67% in the NCRT group, compared to 61.08% and 44.57% in the ACRT group ( p < 0.001). The 5‐ and 10‐year DFS rates were 69.93% and 65.26% in the NCRT group, versus 48.07% and 40.77% in the ACRT group ( p < 0.001). Additionally, in Stage III patients, NCRT was associated with a significant reduction in the risk of death and recurrence compared to ACRT (OS: HR = 0.47, p = 0.0001; DFS: HR = 0.55, p = 0.0001). Conclusion: For patients with Stage III low rectal cancer, NCRT significantly improved the long‐term DFS rate and OS rate, in comparison to adjuvant chemoradiotherapy.
- Open Access
- 21 February 2025
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 23 (1) , 1-6
De novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review
Background: The widespread application of colonoscopy screening and genetic testing in colorectal cancer (CRC) treatment has led to the identification of a subset of familial adenomatous polyposis (FAP) patients who lack a family history of the disease but harbor germline gene mutations. Moreover, distinct genotypes may be associated with varied clinical presentations and therapeutic options. This case report describes a male patient with de novo FAP who harbored germline double heterozygosity (GDH) for APC and BRCA2 mutations. The patient underwent total colectomy, and genetic testing enabled personalized surveillance and management strategies for his family members. Case presentation: A 43-year-old male with no family history of cancer presented to the outpatient clinic of the Colorectal Surgery Department with complaints of constipation and hematochezia. Colonoscopy revealed hundreds of polyps throughout the colon and a rectal adenocarcinoma located 5 cm from the anal verge. Gastroduodenal endoscopy did not detect any upper gastrointestinal adenomas. The patient underwent laparoscopic total colectomy with abdominoperineal resection of the rectum and end ileostomy. With the consent of the patient and his family, genetic testing was performed. The index patient was found to carry an APC splicing site mutation (exon 15: c.1744-1G > A) and a BRCA2 missense mutation (exon 17: c.7976G > A: p.R2659K). His daughter was found to have inherited the same germline BRCA2 variant. Additionally, the rectal cancer exhibited proficient DNA mismatch repair (pMMR) status, ERBB2 copy number amplification, and a missense mutation, while the KRAS, NRAS, and BRAF genes were wild-type. Based on the genetic testing results and clinical manifestations, the index patient was diagnosed with familial adenomatous polyposis (FAP) and rectal cancer. Personalized surveillance and management strategies were implemented for the patient and his family, focusing on the risks of extra-colonic diseases and potential malignancies in the prostate, pancreas, breast, and ovaries. Conclusion: De novo FAP with double germline mutations in APC and BRCA2, along with somatic ERBB2 mutations, is exceptionally rare among hereditary cancer cases. With the rapid advancements in genomics, the detection of multiple gene variants in individuals or families has become increasingly common. Additionally, the application of artificial intelligence (AI) in medical research may provide powerful tools for genetic analysis and clinical decision-making. Consequently, a comprehensive evaluation of family history, a deep understanding of hereditary cancer syndromes, and precise interpretation of genetic mutations are essential for personalized clinical management in the era of precision medicine. However, these tasks pose significant challenges for clinicians and genetic counselors alike.
- 21 February 2025
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 23 (1) , 1-6
Open AccessDe novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review
Background: The widespread application of colonoscopy screening and genetic testing in colorectal cancer (CRC) treatment has led to the identification of a subset of familial adenomatous polyposis (FAP) patients who lack a family history of the disease but harbor germline gene mutations. Moreover, distinct genotypes may be associated with varied clinical presentations and therapeutic options. This case report describes a male patient with de novo FAP who harbored germline double heterozygosity (GDH) for APC and BRCA2 mutations. The patient underwent total colectomy, and genetic testing enabled personalized surveillance and management strategies for his family members. Case presentation: A 43-year-old male with no family history of cancer presented to the outpatient clinic of the Colorectal Surgery Department with complaints of constipation and hematochezia. Colonoscopy revealed hundreds of polyps throughout the colon and a rectal adenocarcinoma located 5 cm from the anal verge. Gastroduodenal endoscopy did not detect any upper gastrointestinal adenomas. The patient underwent laparoscopic total colectomy with abdominoperineal resection of the rectum and end ileostomy. With the consent of the patient and his family, genetic testing was performed. The index patient was found to carry an APC splicing site mutation (exon 15: c.1744-1G > A) and a BRCA2 missense mutation (exon 17: c.7976G > A: p.R2659K). His daughter was found to have inherited the same germline BRCA2 variant. Additionally, the rectal cancer exhibited proficient DNA mismatch repair (pMMR) status, ERBB2 copy number amplification, and a missense mutation, while the KRAS, NRAS, and BRAF genes were wild-type. Based on the genetic testing results and clinical manifestations, the index patient was diagnosed with familial adenomatous polyposis (FAP) and rectal cancer. Personalized surveillance and management strategies were implemented for the patient and his family, focusing on the risks of extra-colonic diseases and potential malignancies in the prostate, pancreas, breast, and ovaries. Conclusion: De novo FAP with double germline mutations in APC and BRCA2, along with somatic ERBB2 mutations, is exceptionally rare among hereditary cancer cases. With the rapid advancements in genomics, the detection of multiple gene variants in individuals or families has become increasingly common. Additionally, the application of artificial intelligence (AI) in medical research may provide powerful tools for genetic analysis and clinical decision-making. Consequently, a comprehensive evaluation of family history, a deep understanding of hereditary cancer syndromes, and precise interpretation of genetic mutations are essential for personalized clinical management in the era of precision medicine. However, these tasks pose significant challenges for clinicians and genetic counselors alike.
- Open Access
- 9 October 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-9
CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?
Locally advanced rectal cancer (LARC) poses unique challenges in treatment, with current neoadjuvant chemoradiotherapy (NA-CRT) showing limitations. The CapeOX regimen emerges as a potential less aggressive neoadjuvant chemotherapy (NAC) for LARC. We conducted a retrospective study involving treatment-naïve patients with LARC from March 2014 to March 2021 who received 2–4 cycles of CapeOX NAC followed by radical surgery. Treatment response was evaluated using tumor regression grade (TRG), MRI-based TRG (MRI-TRG), and Neoadjuvant Rectal (NAR) score. 94.7% of patients experienced symptom improvement and 96.4% achieved sphincter-preserving surgery. Post-NAC showed significant tumor regression and MRI confirmed a tumor length reduction (P < 0.001). Clinical and pathological staging discrepancies post-NAC suggest broader therapeutic advantages. 5-year overall and disease-free survival rates were 78.4% and 73.4%. NAR scores provided better prognostic accuracy than MRI-TRG. CapeOX NAC presents notable benefits for LARC patients and its clinical significance may be underestimated. The NAR score demonstrates superior prognostic value over MRI-TRG.
- 9 October 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-9
Open AccessCapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?
Locally advanced rectal cancer (LARC) poses unique challenges in treatment, with current neoadjuvant chemoradiotherapy (NA-CRT) showing limitations. The CapeOX regimen emerges as a potential less aggressive neoadjuvant chemotherapy (NAC) for LARC. We conducted a retrospective study involving treatment-naïve patients with LARC from March 2014 to March 2021 who received 2–4 cycles of CapeOX NAC followed by radical surgery. Treatment response was evaluated using tumor regression grade (TRG), MRI-based TRG (MRI-TRG), and Neoadjuvant Rectal (NAR) score. 94.7% of patients experienced symptom improvement and 96.4% achieved sphincter-preserving surgery. Post-NAC showed significant tumor regression and MRI confirmed a tumor length reduction (P < 0.001). Clinical and pathological staging discrepancies post-NAC suggest broader therapeutic advantages. 5-year overall and disease-free survival rates were 78.4% and 73.4%. NAR scores provided better prognostic accuracy than MRI-TRG. CapeOX NAC presents notable benefits for LARC patients and its clinical significance may be underestimated. The NAR score demonstrates superior prognostic value over MRI-TRG.
- Top Cited Papers
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (28) , 3308-3318
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
PURPOSE: To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC). PATIENTS AND METHODS: We conducted a prospective, multicenter, randomized, open-label, phase II trial using a pick-the-winner design. Eligible patients with clinical T3-4 and/or N+ rectal adenocarcinoma were randomly assigned to group A for short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab or to group B for two cycles of induction immunochemotherapy followed by SCRT and the rest four doses. Either total mesorectal excision or WW was applied on the basis of tumor response. The primary end point was CR which included pathological CR (pCR) after surgery and clinical CR (cCR) if WW was applicable, with hypothesis of an increased CR of 40% after iTNT compared with historical data of 25% after conventional TNT. RESULTS: Of the 130 patients enrolled, 121 pMMR/MSS patients were evaluable (62 in group A and 59 in group B). At a median follow-up of 19 months, CR was achieved at 56.5% in group A and 54.2% in group B. Both groups fulfilled the predefined statistical hypothesis ( P < .001). Both groups reported a pCR rate of 50%. Respectively, 15 patients in each group underwent WW and remained disease free. The most frequent grade 3 to 4 toxicities were thrombocytopenia and neutropenia. Patients in group A had higher rate of cCR (43.5% v 35.6%) at restaging and lower rate of grade 3 to 4 thrombocytopenia (24.2% v 33.9%) during neoadjuvant treatment. CONCLUSION: The iTNT regimens remarkably improved CR rates in pMMR/MSS LARC compared with historical benchmark with acceptable toxicity. Up-front SCRT followed by immunochemotherapy was selected for future definitive study.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (28) , 3308-3318
Top Cited PapersRandomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
PURPOSE: To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC). PATIENTS AND METHODS: We conducted a prospective, multicenter, randomized, open-label, phase II trial using a pick-the-winner design. Eligible patients with clinical T3-4 and/or N+ rectal adenocarcinoma were randomly assigned to group A for short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab or to group B for two cycles of induction immunochemotherapy followed by SCRT and the rest four doses. Either total mesorectal excision or WW was applied on the basis of tumor response. The primary end point was CR which included pathological CR (pCR) after surgery and clinical CR (cCR) if WW was applicable, with hypothesis of an increased CR of 40% after iTNT compared with historical data of 25% after conventional TNT. RESULTS: Of the 130 patients enrolled, 121 pMMR/MSS patients were evaluable (62 in group A and 59 in group B). At a median follow-up of 19 months, CR was achieved at 56.5% in group A and 54.2% in group B. Both groups fulfilled the predefined statistical hypothesis ( P < .001). Both groups reported a pCR rate of 50%. Respectively, 15 patients in each group underwent WW and remained disease free. The most frequent grade 3 to 4 toxicities were thrombocytopenia and neutropenia. Patients in group A had higher rate of cCR (43.5% v 35.6%) at restaging and lower rate of grade 3 to 4 thrombocytopenia (24.2% v 33.9%) during neoadjuvant treatment. CONCLUSION: The iTNT regimens remarkably improved CR rates in pMMR/MSS LARC compared with historical benchmark with acceptable toxicity. Up-front SCRT followed by immunochemotherapy was selected for future definitive study.
- Open Access
- 7 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (10) , 1780-1791
Approaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma
To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient and sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples were examined by immunohistochemistry (IHC) and next‐generation sequencing (NGS), and MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing was performed in cases with deleterious variants and large genomic rearrangements (LGRs) of tumor MMR genes were detected in cases with dMMR or MSI‐H cases with no MMR germline variants. Our results showed that triage with IHC and followed by BRAF/MLH1 methylation testing (Strategy 1) identified 93.3% (70/75) of LS cases. IHC followed by germline NGS (Strategy 2) or direct tumor NGS (Strategy 3) both identified 98.7% (74/75) of LS cases. The proportion of LGRs in LS cases was 16.0% (12/75), while 84.0% (63/75) showed SNV/Indel. The average cost per patient was ¥6010.81, ¥6058.48, and ¥8029.98 for Strategy 1, Strategy 2 and Strategy 3, respectively. The average time spent on different strategies was 4.74 days (Strategy 1), 4.89 days (Strategy 2), and 14.50 days (Strategy 3) per patient, respectively. LS and Lynch‐like syndrome (LLS) were associated with an earlier onset age than MPH. In conclusion, we compared different workflows for LS screening and IHC plus germline NGS is recommended for LS screening when taking sensitivity, time, and cost into account. Moreover, multiplex ligation‐dependent probe amplification made up for the shortcoming of NGS and should be incorporated into routine screening.
- 7 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (10) , 1780-1791
Open AccessApproaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma
To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient and sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples were examined by immunohistochemistry (IHC) and next‐generation sequencing (NGS), and MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing was performed in cases with deleterious variants and large genomic rearrangements (LGRs) of tumor MMR genes were detected in cases with dMMR or MSI‐H cases with no MMR germline variants. Our results showed that triage with IHC and followed by BRAF/MLH1 methylation testing (Strategy 1) identified 93.3% (70/75) of LS cases. IHC followed by germline NGS (Strategy 2) or direct tumor NGS (Strategy 3) both identified 98.7% (74/75) of LS cases. The proportion of LGRs in LS cases was 16.0% (12/75), while 84.0% (63/75) showed SNV/Indel. The average cost per patient was ¥6010.81, ¥6058.48, and ¥8029.98 for Strategy 1, Strategy 2 and Strategy 3, respectively. The average time spent on different strategies was 4.74 days (Strategy 1), 4.89 days (Strategy 2), and 14.50 days (Strategy 3) per patient, respectively. LS and Lynch‐like syndrome (LLS) were associated with an earlier onset age than MPH. In conclusion, we compared different workflows for LS screening and IHC plus germline NGS is recommended for LS screening when taking sensitivity, time, and cost into account. Moreover, multiplex ligation‐dependent probe amplification made up for the shortcoming of NGS and should be incorporated into routine screening.
- Open Access
- 30 April 2024
- Published by Elsevier in EBioMedicine
- Vol. 103, 105142
Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms
- 30 April 2024
- Published by Elsevier in EBioMedicine
- Vol. 103, 105142
Open AccessMicrosatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms
- Open Access
- 17 April 2024
- Published by Springer Nature in Research Square
LncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3
5-Fluorouracil (5-FU) resistance has always been a formidable obstacle in the adjuvant treatment of advanced colorectal cancer (CRC), significantly compromising the patients’ prognosis. In recent years, long non-coding RNAs (lncRNAs) have emerged as key regulators in various pathophysiological processes, particularly in cancers. However, the precise molecular mechanisms governed by these molecules in 5-FU resistance remain insufficiently elucidated. In this study, RNA-seq combined with weighted gene correlation network analysis (WGCNA) confirmed the close association of GAS6-AS1 with TRG grades. GAS6-AS1 expression was positively correlated with advanced clinicopathological features and poor prognosis in CRC. GAS6-AS1 increased the 50% inhibiting concentration (IC50) of 5-FU, enhanced cell proliferation, and accelerated G1/S transition in CRC cells, both with and without 5-FU, both in vitro and in vivo. Mechanistically, GAS6-AS1 enhanced the stability of MCM3 mRNA by recruiting PCBP1, consequently increasing MCM3 expression. Furthermore, PCBP1 and MCM3 counteracted the effects of GAS6-AS1 on 5-FU resistance. Notably, the PDX model indicated that combining chemotherapeutic drugs with GAS6-AS1 knockdown yielded superior outcomes in vivo. Taken together, our findings elucidate that GAS6-AS1 directly binds to PCBP1, enhancing MCM3 expression and thereby promoting 5-FU resistance in CRC. GAS6-AS1 may serve as a robust biomarker and potential therapeutic target for combination drug therapy in CRC.
- 17 April 2024
- Published by Springer Nature in Research Square
Open AccessLncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3
5-Fluorouracil (5-FU) resistance has always been a formidable obstacle in the adjuvant treatment of advanced colorectal cancer (CRC), significantly compromising the patients’ prognosis. In recent years, long non-coding RNAs (lncRNAs) have emerged as key regulators in various pathophysiological processes, particularly in cancers. However, the precise molecular mechanisms governed by these molecules in 5-FU resistance remain insufficiently elucidated. In this study, RNA-seq combined with weighted gene correlation network analysis (WGCNA) confirmed the close association of GAS6-AS1 with TRG grades. GAS6-AS1 expression was positively correlated with advanced clinicopathological features and poor prognosis in CRC. GAS6-AS1 increased the 50% inhibiting concentration (IC50) of 5-FU, enhanced cell proliferation, and accelerated G1/S transition in CRC cells, both with and without 5-FU, both in vitro and in vivo. Mechanistically, GAS6-AS1 enhanced the stability of MCM3 mRNA by recruiting PCBP1, consequently increasing MCM3 expression. Furthermore, PCBP1 and MCM3 counteracted the effects of GAS6-AS1 on 5-FU resistance. Notably, the PDX model indicated that combining chemotherapeutic drugs with GAS6-AS1 knockdown yielded superior outcomes in vivo. Taken together, our findings elucidate that GAS6-AS1 directly binds to PCBP1, enhancing MCM3 expression and thereby promoting 5-FU resistance in CRC. GAS6-AS1 may serve as a robust biomarker and potential therapeutic target for combination drug therapy in CRC.
- Open Access
- 22 March 2024
- Published by Elsevier in Cancer Letters
- Vol. 589, 216828
LncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3
- 22 March 2024
- Published by Elsevier in Cancer Letters
- Vol. 589, 216828
Open AccessLncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3